The agreement has been signed between the Quebec-based company and Diversified Natural Products and Thorne Research for distribution to dermatology clinics, health practitioners and health food stores in the US. The new deal comes after an agreement in principle with PhotoMedex for US distribution fell through in 2006. The distributor was not able to meet the terms of the agreement. "The US market is our top priority for 2007 and this agreement validates Advitech's determination to penetrate the US market as early as the 3rd quarter of 2007," said Renaud Beauchesne. Dermylex is a patented blend of naturally derived bioactive peptides that comes in the form of a tablet to be taken orally. While the company originally designed an ingredient, it has increasingly shifted promotion towards its own finished psoriasis product. After numerous years of development, Advitech has begun to roll out Dermylex via distribution agreements with companies such as Canadian Jamieson Laboratories. As well, the company has secured numerous athletic spokespeople to represent the branded product. An estimated 6 million adults in North America suffer from the skin disease psoriasis, potentially opening-up a large market for a natural oral alternative, such as Dermylex, to target the condition. As such, the current deal represents a coup of sorts for the company in terms of breaking into new waters in the US. New York-based DNP markets specialty ingredients and Thorne specializes in the health practitioners segment. "This approach in two separate distribution networks with Thorne and DNP will allow Dermylex, a product with validated clinical studies and strong science, to be professionally referred for psoriasis patients, through dermatology clinics and by health practitioners while, also being available in specialized health food stores across the US," said Beauchesne.